Researchers pinpoint why lymphoma patients may become resistant to specific therapy

(H. Lee Moffitt Cancer Center& Research Institute) Researchers from Moffitt Cancer Center and Dana-Farber Cancer Institute have discovered a mechanism of drug resistance to Venetoclax ® , also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. Their findings, published in the journal Cancer Cell, also suggest a possible co-treatment strategy to overcome this resistance.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news